Results 41 to 50 of about 7,378 (198)

Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis : A Prospective Cohort Study [PDF]

open access: yes, 2017
Background: Paediatric ulcerative colitis [UC] is more extensive than adult disease, and more often refractory to mesalamine. However, no prospective trials have evaluated mesalamine enemas for inducing remission in children. Our goal was to evaluate the
Shamaly, Hussein   +35 more
core   +1 more source

Proteomic profile of human colon organoids: effects of a multi-mineral intervention alone and in the presence of pro-inflammatory and anti-inflammatory treatments

open access: yesFrontiers in Gastroenterology
IntroductionAquamin, a multi-mineral product derived from fossilized red marine algae, has been shown to improve colon barrier structure and function.
Muhammad Nadeem Aslam   +5 more
doaj   +1 more source

One of the 5-aminosalicylates drug, mesalamine as a drug repurposing lead against breast cancer

open access: yesBulletin of the National Research Centre, 2022
Background Breast cancer is the world's second leading cause of death in women. The problem of chemoresistance in breast cancer is proving to be a challenge for researchers and several oncologists all around the world.
Dayanand Swami   +4 more
doaj   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

open access: yesJPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan   +2 more
wiley   +1 more source

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Among 200 patients with primary sclerosing cholangitis, 38% reported moderate to severe pruritus in the past 6 months. During 6 months of follow up, pruritus severity fluctuated significantly. Pruritus severity was linked to worse colitis activity and lower quality of life.
Richard Dean   +16 more
wiley   +1 more source

The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.

open access: yesPLoS ONE, 2014
UnlabelledThe anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and ...
Ma Somsouk   +15 more
doaj   +1 more source

Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake   +4 more
wiley   +1 more source

Case Report of a Rapidly Progressive Indolent T‐Cell Lymphoma of the Gastrointestinal Tract

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Indolent T‐cell lymphoma of the gastrointestinal tract (iTCL‐GI) is a relatively newly recognized disease entity. iTCL‐GI was first proposed by Perry et al. in 2013, before it was formally incorporated as a distinct disease category in the fifth edition of the World Health Organization Classification of Hematolymphoid Tumors: Lymphoid ...
Keitaro Shibuya   +9 more
wiley   +1 more source

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

open access: yesClinical Pharmacology: Advances and Applications, 2019
Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg ...
Jakate A, McNamee B, Burkindine D
doaj  

Efficacy and Tolerance of 5-Aminosalicylic Acid Suppositories in the Treatment of Ulcerative Proctitis: A Review of Two Double-Blind, Placebo Controlled Trials

open access: yesCanadian Journal of Gastroenterology, 1990
The efficacy and tolerance of 500 mg 5-aminosalicylic acid (mesalamine) suppositories in the treatment of ulcerative proctitis were assessed in two double-blind, placebo controlled studies of six weeks' duration, involving a total of 173 patients.
CN Williams
doaj   +1 more source

Home - About - Disclaimer - Privacy